[go: up one dir, main page]

IS4978A - Aðferð til meðhöndlunar á stækkun blöðruhálskirtils og krabbameini í blöðruhálskirtli - Google Patents

Aðferð til meðhöndlunar á stækkun blöðruhálskirtils og krabbameini í blöðruhálskirtli

Info

Publication number
IS4978A
IS4978A IS4978A IS4978A IS4978A IS 4978 A IS4978 A IS 4978A IS 4978 A IS4978 A IS 4978A IS 4978 A IS4978 A IS 4978A IS 4978 A IS4978 A IS 4978A
Authority
IS
Iceland
Prior art keywords
prostate
treatment
enlargement
prostate cancer
cancer
Prior art date
Application number
IS4978A
Other languages
English (en)
Inventor
Engel Jürgen
Reissmann Thomas
Riethmüller-Winzen Hilde
Rawert Jürgen
Original Assignee
Zentaris Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh. filed Critical Zentaris Gmbh.
Publication of IS4978A publication Critical patent/IS4978A/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IS4978A 1996-09-12 1999-02-16 Aðferð til meðhöndlunar á stækkun blöðruhálskirtils og krabbameini í blöðruhálskirtli IS4978A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2599096P 1996-09-12 1996-09-12
US4322897P 1997-04-10 1997-04-10
PCT/EP1997/004740 WO1998010781A1 (en) 1996-09-12 1997-09-01 Means for treating prostate hypertrophy and prostate cancer

Publications (1)

Publication Number Publication Date
IS4978A true IS4978A (is) 1999-02-16

Family

ID=26700570

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4978A IS4978A (is) 1996-09-12 1999-02-16 Aðferð til meðhöndlunar á stækkun blöðruhálskirtils og krabbameini í blöðruhálskirtli

Country Status (28)

Country Link
US (4) US6054432A (is)
EP (1) EP0925069B1 (is)
JP (1) JP2001500500A (is)
KR (1) KR100546235B1 (is)
CN (1) CN1126566C (is)
AR (1) AR009757A1 (is)
AT (1) ATE370743T1 (is)
AU (1) AU738306B2 (is)
BR (1) BR9713197A (is)
CA (1) CA2215015A1 (is)
CZ (1) CZ298738B6 (is)
DE (1) DE69738045T2 (is)
DK (1) DK0925069T3 (is)
EE (1) EE04000B1 (is)
ES (1) ES2289764T3 (is)
HU (1) HUP0000261A3 (is)
IL (3) IL128331A0 (is)
IS (1) IS4978A (is)
MX (1) MXPA99002420A (is)
NO (1) NO326207B1 (is)
NZ (1) NZ334540A (is)
PL (1) PL193184B1 (is)
PT (1) PT925069E (is)
RU (1) RU2215537C2 (is)
SK (1) SK286174B6 (is)
TR (1) TR199900556T2 (is)
TW (1) TWI224002B (is)
WO (1) WO1998010781A1 (is)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US6054432A (en) * 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer
FR2768055A1 (fr) * 1997-09-11 1999-03-12 Synthelabo Utilisation de derives de sulfonanilide pour obtenir un medicament destine au traitement de l'ejaculation retrograde ou de l'aspermie
TW536402B (en) * 1998-06-26 2003-06-11 Yamanouchi Pharma Co Ltd Pharmaceutical composition for the therapy of voiding dysfunction
DE19911771B4 (de) * 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
US6545034B1 (en) * 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
US7129262B2 (en) * 1999-07-23 2006-10-31 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7105560B1 (en) 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma
US7151100B1 (en) * 1999-07-23 2006-12-19 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7361680B2 (en) * 1999-07-23 2008-04-22 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
ID30249A (id) * 1999-08-09 2001-11-15 Yamanouchi Pharma Co Ltd Komposisi farmasi untuk terapi gejala-gejala penyakit pelaksanaan fungsi saluran air kencing bawah
CA2669753C (en) 1999-09-30 2012-06-26 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
DE10040700A1 (de) * 2000-08-17 2002-02-28 Asta Medica Ag Salze von biologisch aktiven Peptiden, ihre Herstellung und Verwendung
KR100876538B1 (ko) * 2000-08-17 2008-12-31 아에테르나 젠타리스 게엠베하 Lhrh 길항제의 염의 제조방법
JP2001288115A (ja) * 2001-02-07 2001-10-16 Yamanouchi Pharmaceut Co Ltd 下部尿路症治療剤
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
US7211599B2 (en) * 2002-09-19 2007-05-01 The Regents Of The University Of California Use of etodolac to treat hyperplasia
GB0301016D0 (en) * 2003-01-16 2003-02-19 Univ London Treatment of benign prostatic hyperplasia
MXPA05007572A (es) 2003-01-17 2005-11-17 Threshold Pharmaceuticals Inc Tratamiento de hiperplasia prostatica benigna.
CN101677975B (zh) * 2006-05-03 2013-06-26 威斯康星校友研究基金会 N1,n4-双(丁-1,3-二烯基)丁-1,4-二胺药物组合物及其方法
EP1891964A1 (en) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP1967202A1 (en) * 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
EP2095818A1 (en) * 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
US10585101B2 (en) 2016-03-10 2020-03-10 Wavesense, Inc. Prostatic liquid biopsy for the detection of prostate cancer and benign prostatic hyperplasia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2465486A1 (fr) * 1979-09-21 1981-03-27 Roussel Uclaf Nouvelle application utilisant la lh-rh ou des agonistes
HU199694B (en) * 1988-05-10 1990-03-28 Innofinance Altalanos Innovaci Process for producing citostatic pharmaceutical compositions containing gonadoliberin derivatives
DE3918543A1 (de) * 1989-06-07 1990-12-13 Boehringer Mannheim Gmbh Verwendung von naftopidil zur therapie der dysurie bei benigner prostata-hypertrophie
IL101245A0 (en) * 1991-03-20 1992-11-15 Merck & Co Inc Pharmaceutical compositions for the treatment of prostatic cancer
IL101243A (en) * 1991-03-20 1999-12-22 Merck & Co Inc Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history
US6054432A (en) * 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer

Also Published As

Publication number Publication date
EP0925069B1 (en) 2007-08-22
IL128331A0 (en) 2000-01-31
PL332085A1 (en) 1999-08-30
CA2215015A1 (en) 1998-03-12
HK1021937A1 (en) 2000-07-21
US6071882A (en) 2000-06-06
HUP0000261A2 (hu) 2000-10-28
CN1230121A (zh) 1999-09-29
MXPA99002420A (es) 2004-08-27
NO991192D0 (no) 1999-03-11
DE69738045D1 (de) 2007-10-04
DE69738045T2 (de) 2008-05-15
CN1126566C (zh) 2003-11-05
US6054432A (en) 2000-04-25
HUP0000261A3 (en) 2001-03-28
WO1998010781A1 (en) 1998-03-19
NZ334540A (en) 2000-07-28
PT925069E (pt) 2007-10-17
ATE370743T1 (de) 2007-09-15
ES2289764T3 (es) 2008-02-01
TWI224002B (en) 2004-11-21
AU4619897A (en) 1998-04-02
AU738306B2 (en) 2001-09-13
IL128331A (en) 2010-05-31
CZ298738B6 (cs) 2008-01-09
EE9900121A (et) 1999-10-15
BR9713197A (pt) 2000-04-04
PL193184B1 (pl) 2007-01-31
RU2215537C2 (ru) 2003-11-10
JP2001500500A (ja) 2001-01-16
NO326207B1 (no) 2008-10-20
US6300313B1 (en) 2001-10-09
EP0925069A1 (en) 1999-06-30
IL189132A0 (en) 2008-06-05
CZ80899A3 (cs) 1999-11-17
DK0925069T3 (da) 2007-10-29
US5998377A (en) 1999-12-07
NO991192L (no) 1999-04-28
TR199900556T2 (xx) 1999-07-21
SK30199A3 (en) 2000-03-13
KR100546235B1 (ko) 2006-01-26
EE04000B1 (et) 2003-04-15
AR009757A1 (es) 2000-05-03
KR20010029495A (ko) 2001-04-06
SK286174B6 (sk) 2008-04-07

Similar Documents

Publication Publication Date Title
IS4978A (is) Aðferð til meðhöndlunar á stækkun blöðruhálskirtils og krabbameini í blöðruhálskirtli
NO994069D0 (no) Forbindelser for immunoterapi av prostatacancer og fremgangsmåte for anvendelse derav
NO984229D0 (no) Forbindelser og fremgangsmÕter for immunoterapi og immunodiagnose av prostatakreft
NO973265D0 (no) Anordning for komplettering av underjordisk brönn og tilhörende fremgangsmåte
NO20014897D0 (no) Metode til fremkallelse av kreftcelledöd og tumorregresjon
NO983576D0 (no) Brönnbehandlingsfluider og fremgangsmåter
NO971015L (no) Forbindelser og metoder for behandling av cancer
NO992297D0 (no) FremgangsmÕte og nye forbindelser
NO20005057L (no) FremgangsmÕte og innretning for Õ stimulere en underjordisk formasjon
NO973464D0 (no) Forlengingsrör - avskraperpluggapparat og fremgangsmåte
NO984150D0 (no) Elektrisk brönnloggefluid og fremgangsmåte for anvendelse derav
IS5025A (is) Samtengd efnasambönd nytsamleg við meðhöndlunina á krabbameini í blöðruhálskirtli
NO975759D0 (no) Inokuleringsmiddel og fremgangsmåte for fremstilling av inokuleringsmiddel
NO981426D0 (no) Fremgangsmåte og anordning for primær-brönn-sementering
IS4731A (is) Kínólín og kínazólín efnasambönd nytsamleg í meðferð
IS2012B (is) Kínólín og kínasólín efnasambönd nytsamleg í meðferð, einkum til að meðhöndla góðkynja vefjaauka í blöðruhálskirtli
IS4805A (is) Aðferð til meðhöndlunar og lyfjasamsetning
IS1930B (is) Notkun samsetningar H+, K+ -ATPasa tálma og sykurstera í meðhöndlun á nefsepagerum
IS5502A (is) Samtengd efnasambönd nytsamleg við meðhöndlun á krabbameini í blöðruhálskirtli
NO993963D0 (no) Anordning og fremgangsmÕte til induksjonsforsegling
NO993030D0 (no) FremgangsmÕte og system for Õ skaffe forbindelser
IS5713A (is) Blöndur prótín-farnesýlfærsluensíms- og HMG COA afoxunarensímstálma og notkun þeirra til meðhöndlunar á krabbameini
NO970634L (no) Blandinger og fremgangsmåter for behandling av hydrokarbon-inneholdende formasjoner
NO982888D0 (no) Sammensetninger og fremgangsmÕter for behandling av underjordiske formasjoner
NO961113D0 (no) Behandling og forebyggelse av prostatakreft